Zoetis Inc. $ZTS Shares Sold by Plato Investment Management Ltd

Plato Investment Management Ltd lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,880 shares of the company’s stock after selling 208 shares during the period. Plato Investment Management Ltd’s holdings in Zoetis were worth $1,312,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in ZTS. Brighton Jones LLC boosted its position in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares during the last quarter. Gotham Asset Management LLC grew its stake in shares of Zoetis by 100.8% in the 4th quarter. Gotham Asset Management LLC now owns 7,973 shares of the company’s stock valued at $1,299,000 after buying an additional 4,002 shares during the period. Obermeyer Wealth Partners increased its holdings in shares of Zoetis by 6.4% during the 4th quarter. Obermeyer Wealth Partners now owns 1,736 shares of the company’s stock worth $283,000 after buying an additional 104 shares during the last quarter. OMERS ADMINISTRATION Corp lifted its holdings in Zoetis by 20.0% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 19,178 shares of the company’s stock valued at $3,125,000 after acquiring an additional 3,190 shares during the last quarter. Finally, Occudo Quantitative Strategies LP purchased a new position in Zoetis in the fourth quarter worth approximately $1,071,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.2%

Zoetis stock opened at $149.45 on Thursday. The firm has a market capitalization of $66.24 billion, a P/E ratio of 25.72, a P/E/G ratio of 2.40 and a beta of 0.89. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The stock’s fifty day simple moving average is $152.70 and its 200-day simple moving average is $157.56.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Argus reiterated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday. Finally, Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.